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Abstract
Background: Clinically useful treatment moderators of Major Depressive Disorder (MDD) have not yet been
identified, though some baseline predictors of treatment outcome have been proposed. The aim of iSPOT-D is to
identify pretreatment measures that predict or moderate MDD treatment response or remission to escitalopram,
sertraline or venlafaxine; and develop a model that incorporates multiple predictors and moderators.
Methods/Design: The International Study to Predict Optimized Treatment - in Depression (iSPOT-D) is a multi-
centre, international, randomized, prospective, open-label trial. It is enrolling 2016 MDD outpatients (ages 18-65)
from primary or specialty care practices (672 per treatment arm; 672 age-, sex- and education-matched healthy
controls). Study-eligible patients are antidepressant medication (ADM) naïve or willing to undergo a one-week
wash-out of any non-protocol ADM, and cannot have had an inadequate response to protocol ADM. Baseline
assessments include symptoms; distress; daily function; cognitive performance; electroencephalogram and event-
related potentials; heart rate and genetic measures. A subset of these baseline assessments are repeated after eight
weeks of treatment. Outcomes include the 17-item Hamilton Rating Scale for Depression (primary) and self-
reported depressive symptoms, social functioning, quality of life, emotional regulation, and side-effect burden
(secondary). Participants may then enter a naturalistic telephone follow-up at weeks 12, 16, 24 and 52. The first half
of the sample will be used to identify potential predictors and moderators, and the second half to replicate and
confirm.
Discussion: First enrolment was in December 2008, and is ongoing. iSPOT-D evaluates clinical and biological
predictors of treatment response in the largest known sample of MDD collected worldwide.
Trial registration: International Study to Predict Optimised Treatment - in Depression (iSPOT-D) ClinicalTrials.gov
Identifier: NCT00693849
URL: http://clinicaltrials.gov/ct2/show/NCT00693849?term=International+Study+to+Predict+Optimized+Treatment
+for+Depression&rank=1
Background
Major depressive disorder (MDD) is the fourth most
disabling medical condition worldwide (based on disabil-
ity-adjusted lifeyears) and is expected to be ranked sec-
ond by year 2020 [1,2]. MDD is typically recurrent,
often chronic and disabling, with a lifetime prevalence
rate of over 15% [3]. Women are approximately twice as
likely to develop MDD as men. MDD is associated with
high health care costs [4]. Antidepressant medications
(ADMs) are effective, [5-9], but only about 50% of
patients with MDD show a response (>50% reduction in
baseline symptoms) and only about one in three attain
remission (virtual absence of symptoms) within the first
eight weeks of treatment [10-12]. Those who do not
attain remission remain at high risk for subsequent
depression, functional impairment and serious general
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medical conditions (GMCs) [13-18]. Several treatments
for MDD are available, but they are currently selected
using a trial-by-trial approach because the field has yet
to identify clinically-useful patient baseline measures
that reliably recommend one treatment over another
(moderators) [19-21]. However, several baseline features
that foretell overall outcome regardless of treatment
type (predictors) have been identified [22-25].
The ongoing International Study to Predict Optimized
Treatment - in Depression (iSPOT-D) is designed to
evaluate a range of potentially useful moderators and/or
predictors within a group of representative outpatients
with nonpsychotic MDD. iSPOT-D is a ‘practical trial’
[26,27] in that it aims to mirror clinical practice in a
representative spectrum of outpatients (to enhance gen-
eralizability). In addition to symptoms, iSPOT-D ana-
lyzes a range of outcomes including function, adverse
events, and side effect burden.
The primary aims of iSPOT-D are to:
1. Identify overall predictors of treatment outcome
(response or remission) after up to eight weeks of
ADM treatment with escitalopram, sertraline or
venlafaxine
2. Identify moderators of treatment outcome
(response or remission) after up to eight weeks of
ADM treatment
3. Develop a model to incorporate the effects of
multiple predictors or moderators on response and
remission
4. Conduct a replication study that utilizes the sec-
ond half of the sample to replicate and confirm the
results of the analyses of the first half (Aims 1-3).
Secondary aims include determining predictors and
moderators of (1) treatment response according to
MDD subtype and (2) symptom severity over time
within the primary study period (baseline to week 8)
and over the more exploratory follow-up period of 12 to
52 weeks.
In addition, a brain imaging sub-study is assessing
10% of participants and matched controls with magnetic
resonance imaging (MRI) and diffusion tensor imaging
(DTI) under rest conditions, and functional MRI under
task conditions, to evaluate neuroanatomical and neural
circuitry measures for diagnostic sensitivity and state
versus trait-like effects from baseline to week 8.
Methods/Design
Organizational Structure
The infrastructure of the iSPOT-D multi-centre, interna-
tional, randomized, prospective, open-label trial includes
the Global Coordinating Center and Data Center (Sydney)
with Global Trial Coordinator and executive management
team; a Molecular Center (Indianapolis); and 20 clinical
sites (see Appendix 1), each with a Principal investigator(s)
and Clinical Trial Coordinator (CTC). Study clinical sites
include clinical research sites within academic settings and
clinical sites in clinical practices. Monitoring visits at each
clinical site are conducted by Clinical Trial Monitors every
eight to 12 weeks (depending on recruitment rates) to
ensure procedural and data integrity.
CTCs at each clinical site assist in the recruitment,
evaluation, management and assessments of participants.
Clinical data are acquired by trained clinicians (psychia-
trists or psychologists) who have passed inter-rater relia-
bility training. The iSPOT-D Executive Committee
oversees the trial, which is supported by the Clinical
Research Organization.
Site selection/training/recruitment
Clinical sites were selected based on the likelihood of
meeting recruitment goals and executing the protocol.
Most sites are practices that do not typically engage in
clinical trials. During a site initiation visit, CTCs at each
site are trained and certified in protocol implementation
and data collection methods. As new staff is added, they
are trained by the Principal Investigator. CTCs work
closely with participants and clinicians, administer some
clinician-rated instruments, ensure that participants
complete all self-rated instruments, and function as
study coordinators (i.e., liaise among sites, Clinical Trial
Monitors and the Global Coordinating Center).
Study Participants
The iSPOT-D study is ongoing, with enrolment having
begun in January 2009. The goal is to recruit 2016 parti-
cipants with nonpsychotic MDD, with 672 in each of
the three treatment groups and 672 age-, sex- and edu-
cation-matched healthy controls. Broad inclusion and
minimal exclusion criteria (Figure 1) are used to recruit
representative adult outpatients with nonpsychotic
MDD who would typically receive ADM in routine
practice. Patients over age 65 are excluded because con-
comitant medical conditions or medications could inter-
act with protocol medications. Adolescents/children are
excluded because the efficacy and safety of most study
ADMs have not been established for this age group.
Ethical Considerations
The study is conducted according to the principles of
the Declaration of Helsinki 2008 (see Appendix 2) the
International Conference on Harmonization (ICH)
guidelines (see Appendix 2) and/or in compliance with
the laws and regulations of the country in which the
research is conducted, including the “Good Clinical
Practice” principles in the US FDA Code of Federal Reg-
ulations (see Appendix 2).
Williams et al. Trials 2011, 12:4
http://www.trialsjournal.com/content/12/1/4
Page 2 of 17
Institutional Review Board (IRB) approval is obtained
prior to patient enrolment at any clinical site. All proto-
col modifications are submitted to each IRB for approval
before implementation. Prior to undertaking any study-
related procedures, each participant receives a verbal
and written explanation of study aims, methods, poten-
tial hazards and benefits from investigators, and pro-
vides written informed consent.
Study Regimens
Enrolment/randomization
Participants are enrolled at each clinical site and rando-
mized to receive escitalopram, sertraline, or venlafaxine-
XR as these ADMs are commonly used in practice
http://www.guidelines.gov and have distinct pharmacolo-
gical properties which may enable the identification of
moderators. Randomization is carried out using Phase-
Forward’s™ validated, Web-based Interactive Response
Technology. A blocked randomization procedure (block
size of 12) is undertaken at the level of the Global Coor-
dinating Center, given that treatment options are equi-
poise across sites. Open treatment is used to ensure
safety and represent clinical practice.
Treatment visits and follow ups
Clinical visits are required at week 0 (baseline) and week
8. Telephone monitoring is undertaken at weeks 2,
4 and 6 to obtain measures of the primary and second-
ary outcomes. Telephone monitoring with these same
Figure 1 Inclusion/Exclusion criteria for iSPOT-D study entry. *DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition
[45]. The term ‘primary diagnosis’ is used in the context of DSM-IV as shorthand to indicate those mental disorders that are not due to a
general medical condition and that are not substance-induced.
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measures is continued in the follow-up period at weeks
12, 16, 24 and 52 (Figure 2).
Protocol Treatment Delivery
iSPOT-D aims to ensure representative but high quality
treatment implementation and maximal participant reten-
tion by collaborating with treating clinicians. Doses for
ADM medications are adjusted by the treating clinicians
according to routine clinical practice, within the following
dose ranges: escitalopram (10 to 20 mg/day), sertraline
(50 to 200 mgday) and venlafaxine-XR (75 to 225 mg/
day). Participants are compensated for each research
assessment (equivalent to $25/1-hour assessment). CTCs
remain in contact with participants to enhance participa-
tion and minimize premature discontinuation. Newslet-
ters and updates are provided to participants on a
monthly basis via e-mail and teleconference, respectively,
to maintain interest and motivation and to enhance
shared learning.
CTCs at each clinical site perform protocol-specified
data gathering and enter data in an electronic case
report form (eCRF) after each clinic visit and telephone
contact. An investigator site file containing all relevant
clinical procedures and study-related documentation has
been supplied to each site to provide clear instructions
on all relevant clinical procedures, including eCRF com-
pletion; psychiatric rating scales; how to perform ECGs;
Serious Adverse Event (SAE) reporting; example tem-
plates of source document collection forms; and logs
used to assist in tracking patient screening, enrolment
and discontinuation targets.
Concurrent Treatments
The study allows additional treatments for associated
symptoms (e.g., insomnia) or medication side effects
(e.g., sexual dysfunction) to reflect common practice.
Participants may receive any treatment for concurrent
GMCs except medications contraindicated for the use of
escitalopram, sertraline or venflaxine-XR. The study
proscribes any concurrent medication likely to affect
brain function recordings and those that cannot be
washed out, including antipsychotics, anticonvulsants,
anxiolytics and clonidine. Data on concomitant medica-
tion are recorded.
Follow-up
All participants are encouraged to continue the same
type and dose of ADM used in the 8 week acute treat-
ment period and to provide telephone-acquired data at
weeks 12, 16, 26 and 52.
Data Collection
Self-report questionnaires and tasks used in cognitive and
electrical brain and autonomic recordings are each based
on well-established constructs in the literature. Unlike
previous trials and experimental research in which these
constructs were assessed using methods that vary across
sites and laboratories, iSPOT-D uses a Web- and compu-
ter-enabled infrastructure to acquire data in a standar-
dized way across participants and sites. Self-report data
are acquired using standardized Web-based question-
naires, cognitive data are obtained using a standardized
computerized touchscreen platform, and electrical brain
and autonomic data are acquired using standardized
hardware and software (see Appendix 2) [28]. The Brain
Resource International Database has been established
using this standardized infrastructure [21,29,30], which
provides a systematic frame of reference for quality con-
trol in the acquisition of all iSPOT-D data.
Screening and Clinical Data
At screening, CTCs gather participant eligibility and
sociodemographic data. The Mini-International Neurop-
sychiatric Interview (MINI-Plus) [31,32] is used to con-
firm DSM-IV criteria for nonpsychotic MDD, and assess
for psychiatric and substance abuse disorders and other
potential exclusion criteria. Depressive symptom severity
is rated using the 17-Item Hamilton Rating Scale for
Depression (HRSD17) [33] and the 16-item Quick Inven-
tory of Depressive Symptomatology-Self Report (QIDS-
SR16) [34-36] (Table 1).
Clinic Visit Moderator and Predictor Data
Molecular Data At baseline, two 6 mL blood samples
are obtained for genotyping. Initial analyses target
Figure 2 Summary of iSPOT-D monitoring of participants.
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300 candidate single nucleotide polymorphisms (SNPs)
that might predict or moderate response to antidepres-
sant medication, including 5HT-2A rs7997013 AA allele,
5HT-2A 102T/CC and -1438A/G G alleles, GRIK4
rs1954787gene, tryptophan hydroxylase (TPH) A218C C
allele [37-39], FKBP5 [40] and CRF1 [41]. Others have
been implicated as a biomarker for non-response to
treatment, including 5HTT-LPR short allele [42],
HTR1A (rs6295) - 1019 G allele, COMT (val108/
158met) Val allele, and the BDNF (brain derived neuro-
trophic factor) [38,39,42-44]. These candidate genomic
variants have also been found to impact the electrical
brain, autonomic and brain imaging measures used in
iSPOT-D in relation to depression [45-47]. Sufficient
blood is collected to also explore gene expression, pro-
teomics and metabolomics. Urine samples are obtained
to provide data on illicit drug use and rule out other
prescription medications (Table 2).
Clinical, Functional Status, and Disposition At the
baseline and week 8 clinic visits, participants complete
the self-report HRSD17 (primary clinical outcome mea-
sure) (see Appendix 2) and secondary outcome measures
including the QIDS-SR16 to assess depressive symptom
severity, the Frequency and Intensity Burden of Side
Effects Rating (FIBSER) [48], the World Health Organiza-
tion Quality Of Life (WHOQoL) scale [49], the Social
Functioning and Adjustment Scale (SOFAS) [50], and the
Emotion Regulation Questionnaire (ERQ) [51] to assess
functional status and measures of disposition (Table 2).
These secondary outcome measures are included in the
Web-based questionnaire battery (see Appendix 2). The
QIDS-SR16 and the FIBSER are also collected during the
telephone monitoring sessions in the acute and follow-up
phases (Figure 2) (see Appendix 2).
Measurement of Self Regulation and Feeling Processes
The Web-based questionnaire battery (baseline and
week 8) includes the Brain Resource Inventory of Social
Cognitions (BRISC) [28,30,47] for assessment of self-reg-
ulation processes. The BRISC contains 45 self-report
items from which scores are obtained for: Negativity
Bias, the tendency to see oneself and one’s world as
negative; Emotional Resilience, self-confidence and the
capacity for coping with life; and Social Skills, the capa-
city for building and maintaining relationships (Table 3).
The BRISC has been normed and validated with regard
to its biological basis [28,30,47]. Participants also com-
plete the full version of the Depression Anxiety and
Stress Scales (DASS), a 42-item instrument that yields
measures of depression, anxiety and stress [52,53],
which has been normed internationally [54].
Cognitive Data for Emotion and Thinking Processes
At baseline and week 8, participants complete cognitive
tasks that assess Emotion and Thinking processes.
Within the Emotion domain, there are two sub-
domains: emotion identification and emotion recogni-
tion (Table 4). The tasks assessing these sub-domains
are, respectively: explicit emotion identification and
implicit emotion recognition [55], yielding both accuracy
(error rates) and reaction time measures. Participants
complete these cognitive tasks using a standard, compu-
terized touchscreen platform (see Appendix 2)
[21,29,30] which does not rely on keyboard or computer
skills. Standardized task instructions are concurrently
presented visually on the screen and via headphones.
Reaction time and accuracy are recorded via the
touchscreen computer and verbal responses via a micro-
phone and recording system attached to the head-
phones. Psychometric properties have been established,
including large norms, validation against traditional
paper and pencil tests tapping equivalent domains, test-
retest reliability, and consistency across cultures [55-60].
Biological validation against brain measures has also
been established in the same participants [56,59,61-63].
The touchscreen cognitive assessments have demon-
strated utility in clinical groups [64-69].
Within the Thinking domain, there are six sub-
domains each assessed by at least one task: response
speed, impulsivity, attention-concentration, information
Table 1 Data Collection at Baseline Screening
Domain Measure Time (minutes) Method Administrator
Consent Consent 15 Interview CTC
Eligibility Inclusion/Exclusion 5 Interview CTC
Psychiatric diagnoses MINI-Plus 45 Interview CTC
Symptoms HRSD17 15 Interview CTC
QIDS-SR16 Web self-report Part
Characteristics Demographics Medical History 10 Web self report Part.
Abbreviations:
CTC = Clinical Trial Coordinator.
MINI-Plus = Mini International Neuropsychiatric Interview - Plus.
HRSD17 = 17-item Hamilton Rating Scale for Depression.
QIDS-SR16 = 16-item Quick Inventory of Depressive Symptomatology - Self-Rated.
Part. = Participant.
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processing efficiency, memory, and executive function-
ing (Table 5). The tasks that assess each sub-domain
yield error, reaction time and task-completion-time
measures.
Electrical Brain and Autonomic data At baseline and
week 8, electrophysiological measures are acquired using
standard pre-specified hardware and software to acquire
data on electroencephalogram (EEG), event-related
potentials (ERPs) elicited by activation tasks, and con-
current autonomic measures of heart rate function and
eye blinks (Table 6).
Electrical brain data Resting EEG and task-activated
ERP data are recorded continuously from 26 scalp sites
with a NuAmps system and QuickCap. Horizontal and
vertical eye movement electrodes are placed near the
eyes.
Resting EEG The resting EEG is recorded for two min-
utes while participants are relaxed with eyes open.
Alpha asymmetry, which has been implicated in depres-
sion [70], is computed by subtracting Alpha power for a
left scalp sites (e.g., left fronto-central sites F3, FC3)
from the homologous right sites (F4, FC4), and dividing
this difference by their sum.
Positive values reflect greater right versus left frontal
alpha power, indicating relatively greater left frontal
activity, since higher alpha power has traditionally been
interpreted as reflecting less cortical activation [70,71].
Maximal asymmetry is indicated with 1.0 and maximal
symmetry is indicated with 0.
Activation task-elicited ERPs ERP components are eli-
cited by each activation task and defined by published
criteria [28,58,72] (Table 7). The primary ERP for each
Table 2 Data Collection at Clinic Visits (Baseline and Week 8): Symptom, Functional Status, Disposition and Molecular
data
Domain Measure Time (minutes) Method Administrator
Symptoms QIDS-SR16 5 Web Self report Part.
Side Effects FIBSER 1 Web Self report Part.
Functional Status WHOQOL 5 Web Self report Part.
SOFAS 3 Web Self report CTC
SWLS 1 Web Self report Part.
ERQ 5 Web Self report Part.
Disposition Early Life Stress 3 Web Self report Part.
Personality traits (NEO-FFI) 5 Web Self report Part.
Molecular* Genomics 10 Blood draw CTC
Drug Screen 8 Urine sample Part.
Abbreviations:
QIDS-SR16 = 16-item Quick Inventory of Depressive Symptoms - Self-Report.
Part. = Participant.
FIBSER = Frequency, Intensity and Burden of Side Effects Rating.
WHOQOL = World Health Organization Quality of Life.
SOFAS = Social Functioning and Adjustment Scale.
SWLS = Satisfaction With Life Scale.
ERQ = Emotion Regulation Questionnaire.
CTC = Clinical Trial Coordinator.
NEO-FFI = NEO Five Factor Inventory.
Table 3 Data Collection at Clinic visits (Baseline and Week 8): Self-Regulation and Feeling data
Domain Measure Time (minutes) Method Administrator
Self Regulation Negativity Biasa 5 Web Self report Part.
Emotional Resilienceb Web Self report Part.
Social Skillsb Web Self report Part.
Feeling DASS Depressiona 7 Web Self report Part.
DASS Anxietya Web Self report Part.
DASS Stressa Web Self report Part.
a Hypothesized contrast is Treatment Responders > Non-Responders.
b Hypothesized contrast is Treatment Responders < Non-Responders.
Abbreviations:
Part. = Participant.
DASS = Depression Anxiety and Stress Scale.
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task is quantified as the maximum amplitude (in micro-
volts) of the change in potential from pre-stimulus base-
line, averaged across task trials to obtain a single value
for each participant.
Autonomic data
Resting heart rate Heart rate is based on an electrocar-
diogram (ECG) (sampling rate of 500 Hz) with electro-
des positioned on the inner left wrist at the radial pulse
and on the right clavicle. ECG is recorded concurrently
with the EEG during the entire resting condition.
Activation Task Heart Rate Heart rate is obtained
concurrently with ERPs during the Oddball, Continuous
Performance, Novelty, Go-No Go and Masked and
Unmasked Emotion tasks (Table 6). Mean heart rate is
quantified as beats per minute for the duration of each
task, which allows a calculation of mean heart rate change
and heart rate variability change between resting and task
conditions.
Brain imaging data Ten percent of participants pro-
vide brain imaging data including structural MRI, func-
tional MRI and DTI, using 3Tesla scanners. Functional
MRI is undertaken with the same Oddball, Go-No Go,
Continuous Performance and Emotion tasks used for
ERP recording. Brain imaging recording will be com-
pleted at Baseline and Week 8. A more comprehensive
description of the brain imaging data will be presented
in a subsequent report.
Research Outcomes
The primary research outcome is treatment response,
defined as a ≥50% decrease from the baseline HRSD17.
Secondary outcomes include remission, defined as a
score of ≤7 on the HRSD17. The secondary endpoint for
remission is a score of ≤5 on the QIDS-SR16. Additional
secondary outcomes include depressive symptoms
(QIDS-SR16), side-effect burden (FIBSER), WHO quality
of life (WHOQoL), social functioning and adjustment
scale (SOFAS), satisfaction with life scale (SWLS) and
the emotion regulation questionnaire (ERQ).
Data Management
Data upload and transfer Data from the eCRF are
entered by site staff into each site’s InForm database,
which are coordinated using the PhaseForward InForm
Table 4 Data collection at Clinic visits (Baseline and Week 8): Cognitive data for Emotion processes
Domain Sub-domain Task Measurea Time (minutes) Method Administrator
Emotion Emotion Identification Explicit Emotion Identificationb Fear Errors 8 Touchscreen Part.
Fear Reaction Time
Anger Errors
Anger Reaction Time
Sad Errors
Sad Reaction Time
Disgust Errors
Disgust Reaction Time
Happy Errors
Happy Reaction Time
Neutral Errors
Neutral Reaction Time
Emotion Emotion Recognition Implicit Emotion Recognitionc Fear Errors Touchscreen Part.
Fear Reaction Time
Anger Errors
Anger Reaction Time
Sad Errors
Sad Reaction Time
Disgust Errors
Disgust Reaction Time
Happy Errors
Happy Reaction Time
Neutral Errors
Neutral Reaction Time
a Hypothesized contrast is Treatment Responders < Non-Responders.
(with a common direction of reduction for poorer accuracy and slowed reaction time).
b Participant identifies the verbal label for each facial emotion.
c Facial emotions are represented and participants determine whether or not they have seen each face before.
Abbreviations:
Part. = Participant.
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protocols and are accessible by the Global Coordinating
Center with password control. The source documents
are retained by each site and will be archived for 15
years beyond study completion, or in accordance with
local regulations, whichever is longest.
Blood samples collected for genomics at each site are
placed immediately into a freezer at -20 degrees Celsius
or colder. They are then sent on dry ice to the Covance
Molecular Coordinating Center (MCC) at Indianapolis,
where they are stored at -70 degrees Celsius. Samples
from non-US sites are forwarded to Indianapolis via
initial storage at Covance sites in Geneva or Singapore.
For the Web-based questionnaire, each self-reported
response entered by participants is logged. For the
touchscreen-based cognitive tests, the computer regis-
ters each touch, press and drag made by the user as
each task is performed and writes these with time
stamps to a log file. Electrical brain and autonomic data
are recorded onto the computer as participants com-
plete each condition and task. The computer registers
each datapoint every 2 ms and writes these data with a
time-stamped log file. All these data are part of the
standard computerized Brain Resource data acquisition
infrastructure, which connects to the Web-enabled data
upload system. Once the CTC clicks ‘submit’, the data
are instantly uploaded as an xml file to the Upload Ser-
ver. From there, data are transferred to the ‘Scoring Ser-
ver’ (see Data Quantification sub-section) and then into
the Data Center database at the Global Coordinating
Center (see Data Storage sub-section).
Data Storage The InForm databases from each site are
collated into the central Data Center database. Quantified
data are written to a robust relational DB2 database,
designed to accept the quantified data from all data mod-
alities. Following quantification, all other measures are
written to the DB2 database. In each modality, quantified
data for storage is in the form of a numerical value. The
database is designed to be scalable and expandable
throughout its life. After completion of the final partici-
pant visit, the Global Trial Coordinator will lock the data.
Data quantification A dedicated ‘Scoring Server’ is in
place for quantifying each type of data for iSPOT-D. The
Table 5 Data collection at Clinic visits (Baseline and Week 8): Cognitive data for ‘Thinking’ processes
Domain Sub-domain Task Measurea Time
(minutes)
Method Administrator
Thinking Response Speed Motor Tapping Number of Taps 30 Touchscreen Part.
Variability of Pause between Taps
Impulsivity Go-NoGo Reaction Time 30 Touchscreen Part.
Variability of Reaction Time
False ‘alarm’ errors
Attention-Concentration Continuous Performance
Test
Reaction Time 30 Touchscreen Part,
False ‘alarm’ errors
False ‘miss’ errors
Information Processing
Efficiency
Switching of Attention Completion Time (digits + letters) 30 Touchscreen Part.
Average Connection Time (digits +
letters)
Errors (digits+letters)
Verbal Interference Part 2- Part 1 Errors 30 Touchscreen Part.
Part 2- Part 1 Reaction Time
Choice Reaction Time Reaction Time 30 Touchscreen Part.
Memory Digit Span Recall Span 30 Touchscreen Part.
Trials correct
Memory Recognition Total immediate recall trials 1-4 30 Touchscreen Part.
Learning rate trials 1-4
Delayed recall trial 7
Executive Function Maze Completion Time 30 Touchscreen Part.
Path Learning Time
Overrun Errors
Total Errors
a Hypothesized contrast is Treatment Responders < Non-Responders.
(with a common direction of reduction for poorer accuracy, reduced variability, and slowed reaction time).
Abbreviations:
Part. = Participant.
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‘Scoring Server’ implements criteria for screening of data
quality and quality control (see Section 6.5 for quality
control details).
Clinical data uploaded to the Data Center from the
InForm database are quantified according to the scoring
manuals for each assessment. Genotyping is undertaken
using a standardized array, which allows custom geno-
typing of SNPs within candidate genes or genomic inter-
vals. Genotyping is expressed as number of alleles (allele
loading), coded according to number of a particular
allele, as 0, 1 or 2 (corresponding to 2, 1 or 0 of another
allele respectively).
Web-based questionnaire data is quantified automati-
cally by the Scoring Server, which has been programmed
with the manual scoring criteria for each scale. Cognitive
data is quantified into reaction time and error scores
automatically using a software program. Verbal responses
recorded via sound files are automatically collated by the
server and allocated to pre-certified trained scorers, who
use text fields (as per dictionary included ‘real’ words) to
transcribe participant responses into the server. Tran-
scription is verified by an independent scorer.
The Scoring Server for Electrical Brain and autonomic
data (in the form of ‘Neuroscan 5’ files) includes a series
of artifact correction and rejection procedures. Low and
high frequency noise is removed by high-pass and low-
pass filters, power line artifact by notch filters, and mus-
cle and blink artifact by second-order blind identification
and canonical correlation analysis. The Scoring Server
also includes quality control software that detects five
additional primary sources of artifact (using thresholds
for abnormal voltage, baseline shifts and kurtosis) for
removal prior to quantifying the data.
EEG, ERP and autonomic measures are quantified by
algorithms in the Scoring Server Software that have
been verified against the gold standard of manual scor-
ing with high inter-scorer reliability. Consensus criteria
for quantification are used [73].
Table 6 Data collection at Clinic visits (Baseline and Week 8): Electrophysiological and Autonomic data
Domain Task Measure* Time
(minutes)
Method Administrator
Electrophysiological
Resting condition Eyes Open Frontal Alpha Asymmetrya
Fronto-parietal Alpha powera
Fronto-parietal Theta powerb
2 EEG CTC
Activation tasks Oddball Fronto-Parietal P300 ERPa 6 ERP CTC
Continuous Performance
Test (CPT)
Frontal P450 ERPa 8 ERP CTC
Novelty Frontal Early P300 ERPa
Go-No Go Frontal N200 ERPa 6 ERP CTC
Emotion (masked,
nonconscious)
Temporo-occipital P120, Fronto-central
VPP ERPb
6 ERP CTC
Emotion (unmasked,
conscious)
Temporo-occipital P120, Fronto-central
VPP ERPb
6 ERP CTC
Startle ‘noise burst’ Fronto-central N100-P200 ERPb 4 ERP CTC
Autonomic
Resting condition Eyes Open Average Heart Ratea
Heart Rate Variabilitya
ECG
Activation tasks Startle Eye blinkb EMG CTC
Oddball, CPT, Novelty,
Go-NoGo,
Emotion (masked,
unmasked)
Average Heart Rate, Heart Rate
Variabilitya
Average Skin conductance levela
ECG Electro-dermal
activity
a Hypothesized contrast is Treatment Responders < Non-Responders.
b Hypothesized contrast is Treatment Responders > Non-Responders.
Abbreviations:
Part. = Participant.
CTC = Clinical Trial Coordinator.
CPT = Continuous Performance Test.
EEG = Electroencephalogram.
ERP = Event Related Potential.
EMG = Electromyogram (Orbicularis Occuli).
ECG = Electrocardiogram.
*These are representative measures based on previous findings; additional EEG measures from other recording sites may also be analyzed.
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Quality Control
All data is de-identified using an 8-digit identification
number - with a session-number suffix - to provide
privacy and confidentiality in accord with relevant
guidelines (see Appendix 2). iSPOT-D has a Quality
Control Review Record to record any queries about the
data and any changes, with reasons. This record will be
kept for at least two years after datalock [74].
Training Quality control of training is overseen by the
Global Coordinating Center. Each CTC is trained on-site
in data acquisition using the eCRF; the MINI-Plus and
HRSD17 with paper forms; and the standardized proto-
cols for the Web-based questionnaire, touchscreen cogni-
tive assessments, and electrophysiological and autonomic
recordings. For accreditation, each CTC must perform at
least one acquisition under the supervision of the Global
Trial Coordinator (or delegated staff from the executive
management) and provide three complete datasets that
meet the quality control criteria of the Data Center.
Acquisition and Upload Quality control for clinical
data acquisition is overseen by a Clinical Research Orga-
nization, PhaseForward, which has on-line data checks
which are activated as soon as the data is submitted to
the InForm database. A Clinical Trial Monitor performs
on-site Source Document Verification to confirm accu-
rate data entry for samples of data, in accordance with
the Monitoring Plan.
Procedural quality control of clinical data is underta-
ken in accordance with ICH Good Clinical Practice
(ICH-GCP) guidelines, overseen by the Global Trial
Coordinator. These controls include safeguarding the
blinding, maintaining a secure system that prevents
unauthorized access to the data, and managing a secure
and audited system that permits authorized changes
which are documented and ensure that no entered data
is deleted. Within these guidelines, an audit trail tracks
each data entry to the InForm database and precludes
changes to the data once entry is confirmed. Reports are
Table 7 Activation Task-Elicited Event Related Potentials
Event
Related
Potentiala
Description Participant Response Measure definition Analysis
Oddball
P300b
Series of 300 tones presented at 75 db
(each 50 ms, ISI = 1 second)
Press a button in
response to high-pitched
tones (1000 Hz), ignore
low-pitched tones (500
Hz)
P300 over the parietal cortex ≈300 ms
after each target stimulus (range: 270-
450 ms)
Amplitude averaged
across target trials for
frontal and parietal
recording sites, Fz
and Pz
Continuous
Performance
P450b
Series of 125 letters (B, C, D or G)
presented sequentially (each 200 ms,
ISI = 2.5 seconds)
Press a button when the
same letter appears twice
in a row
P450, occurring in response to
updating of non-target letters at ≈450
ms after letter (range: 300-550 ms).
Most prominent over frontal brain
regions (71)
Averaged across non-
target letter trials for
the frontal Fz recording
site
Novelty Early
P300
Series of 20 blue and green
checkerboard stimuli presented briefly
(200 ms) and infrequently,
unexpectedly and at random intervals
within the Continuous Performance
Test (ISI = 2 seconds)
No response required P300 occurring 250 ms after novelty
stimuli over medial-central frontal brain
regions (range: 220-320 ms) (72)
Averaged over novelty
trials and over Fz and
Cz recording sites
NoGo N200b 168 stimuli presented sequentially
(200 ms each, ISI = 2 seconds)
Press a button as quickly
as possible for Go stimuli,
don’t press for NoGo
stimuli
N200 occurring ≈200 ms after NoGo
stimuli over fronto-central brain
regions (range: 150-230 ms) (39)
Elicited within the
timescale of ‘automatic’
error detection and
impulsivity (73)
Emotion
P120 and
Emotion VPP
Series of 288 stimuli presented
(3-dimensional facial expressions
depicting fear, anger, disgust, sadness,
happiness or neutral) (500 ms each,
ISI = 767 ms)
Active viewing, no
response required.
P120 occurring around 120 ms over
temporo-occipital sites (range: 80-140
ms)
VPP occurring around 170 ms over
fronto-central sites (range: 120-220 ms)
Average of 32 estimuli
for each emotion for
P120 (T5, T6, O1, O2
sites); VPP Fz, Cz sites)
Startle “noise
burst”
Series of 20 acoustic startle stimuli
(white noise burst at 105 db, 50 ms
duration, ISI = 10-15 seconds)
Startle eye blink: muscle
contraction of the eye
blink reflex as measured
by the electromyogram
(82)
Onset latency, peak amplitude and
peak latency
Averaged across the
20 trials, excluding
non-response trials
a Name of ERP component indicates polarity direction in which the change in potential occurs (P = positive, N = negative, and the number represents the
approximate time [in ms] at which it occurs after each stimulus.
b Participant informed that speed and accuracy are important to the task.
Abbreviations:
ISI = Interstimulus Interval.
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provided to the Data Center confirming the quality con-
trol on each participant in iSPOT-D.
Inter-rater reliability for the primary outcome measure
(HRSD17) is audited for each clinician at each testing
site annually, using an established video-based metho-
dology [75]. Clinicians who differ from the average
across sites are advised by the head statistician at the
Global Coordinating Center of how their rating on
applicable items differs to others and they are allowed
to re-sit the rating exam until they are able to rate
within the bounds of the combined site group. The
quality control of blood sample storage is monitored by
the well-established protocols of Covance laboratories at
the MCC in Indianapolis.
Quality control for the acquisition and upload of
Web-based questionnaire, touchscreen, electrophysiolo-
gical and autonomic data is incorporated in the Upload
Server and Scoring Server software. These protocols also
meet the specifications of the ICH-GCP. Recording
channels with confirmed artifact are set as missing in
the study database. The senior technician has the
authority to override an automatic score in the case of
discrepancy.
For quality control of data scoring, at least 10% of
data for each measure is de-identified, reprocessed and
compared to the original results to ensure reproducibil-
ity with zero-tolerance for error. For auto-scored EEG
and ERP data, trained and accredited hand scorers con-
firm the quantification against criteria from the estab-
lished literature (Brain Resource ERP Scoring Manual,
2010). For accreditation, scorers must have ≥50 hours
experience and have passed reviews of their scoring by
the scoring manager, reporting to the GTC. Any queries
or changes must be approved by the Data Center man-
ager and are recorded in the Quality Control Review
Record.
Analytic Approach
iSPOT-D has been registered and is being conducted as
a single study. However, study aims will be addressed by
a two-step analysis procedure.
Aims 1 through 3 will utilize the first half of the sam-
ple (n = 1,008) to identify potential predictors and mod-
erators. Aim 4 will utilize the second half of the sample
(n = 1,008) to replicate and confirm the results gener-
ated from the analyses of the first half. The four aims of
the study and hypotheses are as follows:
1. Identify overall predictors of treatment outcome
(response or remission) after up to eight weeks of ADM
treatment
The predictive effect of baseline characteristics will be
assessed overall, controlling for any treatment effect.
Regression models will be used to assess the predictive
effect of each characteristic on outcome. Independent
variables in the model will include main fixed effects for
treatment and the possible predictive variable. All effects
will be centered to aid interpretability (+1/2 and -1/2 for
treatment choice and any binary predictor, deviation
from the mean baseline for any ordinal predictor).
A baseline characteristic will be considered a predictor
if the p-value is <.05.
2. Identify moderators of treatment outcome (response or
remission) after eight weeks of ADM treatment
The moderating effect of baseline characteristics will be
assessed separately for each pairwise comparison of
treatment (escitalopram vs. sertraline, escitalopram vs.
venlafaxine-XR, sertraline vs. venlafaxine-XR). Regres-
sion models will be used to assess the moderating effect
of each characteristic on outcome. Independent variables
in the model will include main fixed effects for treat-
ment, the possible moderator variable and the two-way
interaction between the characteristic and treatment. All
effects will be centered to aid interpretability (+1/2 and
-1/2 for treatment choice and any binary moderator,
deviation from the mean baseline for any ordinal mod-
erator). A baseline characteristic will be considered a
moderator if the p-value is <.05.
3. Develop a model to incorporate multiple predictor or
moderator effects on response and remission
Recursive partitioning methods will be used to identify
how various baseline characteristics interact with treat-
ment and with each other in their association with treat-
ment response. The recursive partitioning approach will
be used to develop a decision tree which selects treat-
ment and baseline characteristics with maximization of
the sensitivity and specificity of the decision tree in the
prediction of treatment response, while minimizing the
complexity of the decision tree. The overall sensitivity
and specificity of the tree will be reported, along with
95% confidence intervals for each estimate.
4. Replicate the findings in Aims 1-3
A confirmatory analysis will be conducted and the same
models that were fit in Aims 1 and 2 will be fit to the
data from the relevant comparison in the replication
sample. For example, if gender is identified as a predic-
tor of outcome, then the effect of gender will be exam-
ined as a potential predictor in the replication sample.
For both the initial model and the replication model, a
confidence interval will be estimated for the parameter
estimate for the main effect of the potential predictor
variable model (Aim 1) or for the interaction term in
the model (Aim 2). If the two confidence intervals over-
lap, the results will be considered partially confirmed.
A decision tree will have been generated using data
from the first half of the sample, along with an estimate
of the tree’s overall sensitivity and specificity, and a cal-
culation of a 95% confidence interval for the sensitivity
and specificity. The data from the replication sample
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will be applied to the decision tree from the initial sam-
ple and the sensitivity and specificity will be calculated
along with 95% confidence intervals. If the confidence
intervals from the initial and replication samples over-
lap, the results will be considered partially confirmed.
Specific working hypotheses to test each of the pri-
mary aims of the study are listed below. These hypoth-
eses draw on a theoretical integration of the published
research evidence. From this evidence, ‘candidate mar-
kers’ for predicting and moderating response to antide-
pressants have been identified. To date, studies have
typically examined one candidate marker of antidepres-
sant response and major depressive disorder at a time,
using laboratory-specific measures. By using standar-
dized assessments to assess multiple candidate markers
in the same study and same patients, iSPOT-D provides
enhanced statistical power to identify which markers
contribute the most effect size to predicting and moder-
ating antidepressant response.
For each hypothesis, the primary outcome measure of
response to antidepressants is change on the HRSD17,
and the secondary outcomes are change on the self-
reported QIDS-SR16 and functional outcome measures
(WHOQoL, SOFAS, SWLS, ERQ):
1. Baseline severity of clinical symptoms will predict
acute response to antidepressants, and moderate
response to type of antidepressant, at 8-week follow
up.
2. Baseline psychological features, including exposure
to early life trauma and stress-related temperament,
will predict acute response to antidepressants, and
moderate response to type of antidepressant, at 8-
week follow up.
3. Baseline level of cognitive function on emotion
tasks will predict acute response to antidepressants,
and moderate response to type of antidepressant, at
8-week follow up.
4. Baseline level of cognitive function on thinking
tasks will predict acute response to antidepressants,
and moderate response to type of antidepressant, at
8-week follow up.
5. Baseline degree of asymmetry on the EEG mea-
sure of Alpha power will predict acute response to
antidepressants, and moderate response to type of
antidepressant, at 8-week follow up.
6. Baseline degree of heart rate variability on auto-
nomic measures will predict acute response to anti-
depressants, and moderate response to type of
antidepressant, at 8-week follow up.
7. For genetics, the presence of specific SNP alleles
will predict acute response to antidepressants, and
moderate response to type of antidepressant, at
8-week follow up; the 5HT-2A rs7997013 AA allele,
5HT-2A 102T/CC and -1438A/G G alleles, GRIK4
rs1954787gene, tryptophan hydroxylase (TPH)
A218C C allele, FKBP5 and CRF1 will moderate a
positive response, and the 5HTT-LPR short allele,
HTR1A (rs6295) - 1019 G allele, COMT (val108/
158met) Val allele, and the BDNF (brain derived
neurotrophic factor) will moderate a non-response.
Analyses are planned to test each of the core aims and
hypotheses. The primary outcome measure of response
to antidepressants is change on the HRSD17. The sec-
ondary outcomes are change on the self-reported QIDS-
SR16 and functional outcome measures (WHOQoL,
SOFAS, SWLS, ERQ). Independent measures of clinical
severity, psychological function, EEG and genetics being
tested as predictors/moderators of the independent vari-
ables are listed in Tables 2 to 7. For genetic predictors
and moderators, we have focused on an allele-wise
approach to target those SNPs that have reported asso-
ciations in the literature. Sufficient blood is being col-
lected to also explore genome-wide associations between
antidepressant response and predictor/moderator vari-
ables in future, unplanned analyses.
Sample Size, Power and Effect Size
The primary goal of the proposed study is to identify a
number of characteristics which are differentially asso-
ciated with outcomes across various treatments. This
extends the traditional randomized clinical trials which
directly compare treatments or a study designed to spe-
cifically test the moderating effect of one or more base-
line characteristics. The sample size has been selected to
provide statistical power of at least 89% power to detect
small effects for predictors (odds ratio 1.3 per standard
deviation change in the independent baseline measure)
at an alpha level of p < .05; 94% power to detect med-
ium effects for predictors (odds ratio of 1.5) at an alpha
level of p < .001, 94% power to detect medium effects
for moderator interaction terms (odds ratio of 1.5) at an
alpha level of p < .01. In addition to replication in the
second 1000 participants, we aim to control type I error
by applying effect size criteria for each logistic model
that odds ratios for the main parameter of interest must
exceed 1.3.
Data Monitoring and Safety Reporting
A data and safety monitoring board (DSMB) meets every
two months to monitor various aspects of the study
including participant recruitment, protocol compliance,
and SAEs. The DSMB comprises a minimum of three
members with representation from psychiatrists, primary
care physicians and a statistician. Statisticians at the
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Global Coordinating Centre monitor the age, sex and edu-
cation distributions of each group every month to ensure
matching (±3 years for age, ±1 year for education).
Site recruitment and retention is monitored weekly by
the Global Trial Coordinator and CTC for each site.
Monitoring is undertaken in accordance with ICH-GCP
guidelines. The Monitoring Plan requires 100% source
data verification of SAEs and primary outcome mea-
sures, and a sample of cognition and brain data. All
informed consents are reviewed. Sites that enrol more
participants are monitored more frequently.
The Clinical Research Organization is responsible for
ensuring that the rights and welfare of participants are
maintained, data quality is satisfactory and the trial is
conducted in accordance with ICH-GCP and country-
specific guidelines, as well as with the protocol’s stan-
dard operating procedures.
All SAEs (Figure 3) are recorded in the eCRF and on
the “Serious Adverse Event Report” form. All SAE
entries indicate whether the SAE is serious, the severity,
date of onset, whether it is related to study medication
or procedure, the action being taken, and resolution.
The Global Trial Coordinator may request additional
information from the investigator to ensure the timely
completion of accurate safety reports. SAE follow-up
continues through the last day on study (including the
off-study follow-up medication period) and/or until the
Global Trial Coordinator and Principal Investigator for
the site determine that the participant’s condition is
stable. Brain Resource may request that certain SAEs be
followed until resolution.
The Principal Investigator ensures that all measures
necessary for resolution of the SAE are taken. All medi-
cations necessary for treatment of the SAE are recorded
in the concomitant medication section of the eCRF.
The investigator notifies the Institutional Review
Board or Independent Ethics Committee (in writing) of
SAEs as soon as is practical where this is required by
local regulatory authorities and in accordance with the
local institutional policy. In accordance with the
European Union Clinical Trials Directive (2001/20/EC),
the Sponsor or its designee notifies the Ethics Commit-
tees of the concerned Member States of SAEs that are
unexpected and possibly attributable to the treatment
medication. In all countries, SAEs are reported in accor-
dance with the regulations governing expedited report-
ing for registered products. SAE reporting is monitored
by the Clinical Research Organization and all SAEs are
reviewed by the DSMB.
Discussion
iSPOT-D, a randomized controlled study, aims to iden-
tify moderators and predictors of treatment response
among three treatments: escitalopram, sertraline, and
venlafaxine-XR. Potential moderators or predictors
include measures of depressive symptoms, functional
status, side-effect burden, genomic, cognition, brain
function and brain imaging. Participants are being
recruited from clinical and academic sites to assemble a
broadly inclusive and representative population. Thus,
study results should be widely generalizable.
iSPOT-D includes an innovation in study design with
the use of cognitive, brain and gene measures for the
identification of objective markers that may moderate or
predict response to ADMs. Identifying these markers
will be an important first step in a ‘personalized medi-
cine’ approach to the management of MDD.
Appendices
Appendix 1
Summary of proposed sites for iSPOT-D
USA
Academic Sites:
Stanford University, Department of Psychiatry
Massachusetts Institute of Technology
Harvard University, McLean Hospital
University of St Louis Missouri, Department of
Psychology
Ohio State University
University of Virginia, Center for Psychiatric Clinical
Research
Clinical Sites:
Shanti Clinical Trials, Colton, California
Center for Healing the Human Spirit Tarzana,
California
Skyland Behavioral Health Associates, North
Carolina
NeuroDevelopment Center, Providence RI, Aca-
demic affiliation: Brown University
Brain Resource Center, NYC, Academic affiliation:
Columbia University
Figure 3 Definition of Serious Adverse Events.
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UK
Academic Sites:
Kings College Institute of Psychiatry, London
Netherlands
Clinical Sites:
Brainclinics Diagnostics & Treatment, Nijmegen,
Academic affiliation: Nijmegen University
Australia
Academic Sites:
University of Sydney, Westmead Hospital
Monash University, Melbourne, Alfred Hospital
Swinburne University, Melbourne, Brain Sciences
Institute
Flinders University, Adelaide, Cognitive Neu-
roscience Unit
Clinical Sites:
Mind Medico, Tasmania, Academic affiliation: Uni-
versity of Tasmania
New Zealand
Academic Sites:
Auckand University, Department of Psychiatry
Clinical Sites:
Brain Health, Johannesburg, Academic affiliation:
University of Wittswatersrand
Appendix 2
Regulations/Guidelines, Trademark Names, and Out-
come Measure Details
Regulations/Guidelines
World Medical Association Declaration of Helskini:
http://www.wma.net/en/30publications/10policies/b3/
index.html
ICH Guidelines: http://www.ich.org/home.html
FDA Code of Federal Regulations:
http://www.fda.gov/ScienceResearch/SpecialTopics/
RunningClinicalTrials/ucm114928.htm
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/
cfcfr/cfrsearch.cfm?cfrpart = 312
European Medical Association: http://www.ema.
europa.eu/pdfs/human/ich/013595en.pdf
Australia; Therapeutic Goods Association regulations:
http://www.tga.gov.au/docs/html/ich13595.htm
New Zealand; Medsafe Good Clinical Practice
Guideline and Codes:
http://www.medsafe.govt.nz/profs/regissues.asp
South Africa; Department of Health guidelines:
http://www.doh.gov.za/docs/policy/trials/trials_01.html
Trademark Names for Brain Resource Data Acqui-
sition Methods
• Web-based battery of self-report questionnaires:
WebQ™
• Brain Resource Inventory of Social Cognitions:
BRISC™. The BRISC is a Web-based battery imple-
mented in conjunction with WebQ.
• Computerized cognitive test battery operating on a
touchscreen platform: IntegNeuro™. The version
of ‘IntegNeuro’ that operates in conjunction with
LabNeuro (listed below) has also been called
‘Psychometrics’.
• Computerized resting and task conditions for
recording of EEG, ERPs and autonomic data:
LabNeuro™.
• Standardized sequences and software for MRI,
functional MRI and DTI: MRI-Neuro™.
• Standardized protocols for acquiring and trans-
porting DNA samples for genotyping; Molecular-
Neuro™.
Outcome Measure Details
The supplementary four items contributing to the 21-
item version of the HRSD17 will also be assessed, but
not used as part of the primary outcome score.
Reasons for exit before 8 weeks are recorded. QIDS-
SR16 data will be available for these participants, for the
weeks prior to week 8.
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